Spengler Gabriella, Kincses Annamária, Gajdács Márió, Amaral Leonard
Department of Medical Microbiology and Immunobiology, Faculty of Medicine, University of Szeged, 6720 Szeged, Hungary.
Travel Medicine, Institute of Hygiene and Tropical Medicine, Universidade Nova de Lisboa, 1349-008 Lisbon, Portugal.
Molecules. 2017 Mar 15;22(3):468. doi: 10.3390/molecules22030468.
Multidrug resistance (MDR) has appeared in response to selective pressures resulting from the incorrect use of antibiotics and other antimicrobials. This inappropriate application and mismanagement of antibiotics have led to serious problems in the therapy of infectious diseases. Bacteria can develop resistance by various mechanisms and one of the most important factors resulting in MDR is efflux pump-mediated resistance. Because of the importance of the efflux-related multidrug resistance the development of new therapeutic approaches aiming to inhibit bacterial efflux pumps is a promising way to combat bacteria having over-expressed MDR efflux systems. The definition of an efflux pump inhibitor (EPI) includes the ability to render the bacterium increasingly more sensitive to a given antibiotic or even reverse the multidrug resistant phenotype. In the recent years numerous EPIs have been developed, although so far their clinical application has not yet been achieved due to their in vivo toxicity and side effects. In this review, we aim to give a short overview of efflux mediated resistance in bacteria, EPI compounds of plant and synthetic origin, and the possible methods to investigate and screen EPI compounds in bacterial systems.
多重耐药性(MDR)的出现是对因不正确使用抗生素和其他抗菌药物所产生的选择性压力的一种反应。抗生素的这种不当应用和管理不善已在传染病治疗中引发了严重问题。细菌可通过多种机制产生耐药性,而导致MDR的最重要因素之一是外排泵介导的耐药性。鉴于与外排相关的多重耐药性的重要性,开发旨在抑制细菌外排泵的新治疗方法是对抗具有过度表达的MDR外排系统细菌的一种有前景的途径。外排泵抑制剂(EPI)的定义包括使细菌对给定抗生素越来越敏感甚至逆转多重耐药表型的能力。近年来已开发出许多EPI,尽管到目前为止由于其体内毒性和副作用,它们尚未实现临床应用。在本综述中,我们旨在简要概述细菌中的外排介导耐药性、植物和合成来源的EPI化合物,以及在细菌系统中研究和筛选EPI化合物的可能方法。